TB Facts for Health Care Workers
2006
Return to Table of Contents
Selected Bibliography
American Thoracic Society, Centers for Disease Control and Prevention.
Treatment of Tuberculosis
— MMWR 2003; 52(No. RR-11)
(PDF).
American Thoracic Society.
Diagnostic
standards and classification of TB in adults and children.
(PDF) Am
J Respir Crit Care Med 2000;161:1376‑1395.
Centers for Disease Control and Prevention.
Guidelines for preventing
the transmission of Mycobacterium tuberculosis in health-care
settings, 2005. (PDF) MMWR 2005; 54(No. RR-17).
Centers for Disease Control and Prevention.
Guidelines
for using the Quantiferon®-TB Gold test
for detecting Mycobacterium tuberculosis infection, United
States. (PDF) MMWR 2005; 54(No.
RR-15, 49-55)
Centers for Disease Control and Prevention.
Reported Tuberculosis
in the United
States, 2003.
(PDF) Atlanta,
GA: U.S.
Department of Health and Human Services, CDC; 2004.
Centers for Disease Control and Prevention.
Updated Guidelines
for the Use of Rifamycins for the Treatment of Tuberculosis Among
HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside
Reverse Transcriptase Inhibitors. 2004.
(PDF) MMWR 2004; 53(No.
02).
Centers for Disease Control and Prevention.
Tuberculosis Associated
with Blocking Agents Against Tumor Necrosis Factor-Alpha --- California, 2002—2003.
(PDF) MMWR 2004; 53(No.
30).
Centers for Disease Control and Prevention.
Update: Adverse
event data and revised American Thoracic Society/CDC recommendations
against the use of rifampin and pyrazinamide for treatment of latent
tuberculosis infection.
(PDF) MMWR 2003; 52(No.
31).
Centers for Disease Control and Prevention.
Guidelines for environmental
infection control in health-care facilities.
(PDF) MMWR 2003; 52(No.
RR-10).
Centers for Disease Control and Prevention.
Guidelines for the
prevention of opportunistic infections among HIV-infected persons
--- 2002. (PDF) MMWR 2002; 51(No.
RR-08).
Centers for Disease Control and Prevention.
Revised guidelines
for HIV counseling, testing, and referral.
(PDF)
MMWR
2001; 50(No. RR-19).
Centers for Disease Control and Prevention.
Targeted tuberculin testing and treatment of latent tuberculosis
infection. (PDF) MMWR 2000; 49(No. RR-06).
Centers for Disease Control and Prevention.
Prevention and treatment
of tuberculosis among patients infected with human immunodeficiency
virus: principles of therapy and revised recommendations.
(PDF) MMWR
1998; 47(No.RR- 20).
Centers for Disease Control and Prevention.
Anergy skin testing
and preventive therapy for HIV-infected persons: revised recommendations.
(PDF)
MMWR 1997; 46(No.
RR-15).
Centers for Disease Control and Prevention.
The role of BCG vaccine
in the prevention and control of tuberculosis in the United States: a joint statement by the Advisory
Council for the Elimination of Tuberculosis and the Advisory Committee
on Immunization Practices. (PDF) MMWR 1996; 45(No. RR-04).
Centers for Disease Control and Prevention.
Management of persons
exposed to multidrug-resistant tuberculosis. MMWR
1992; 41(No. RR-11).
Lambert L, Rajbhandary S, Qualls N, Budnick L, Catanzaro A, Cook
S, Daniels-Cuevas L, Garber E, Reves R. Costs of implementing
and maintaining a tuberculin skin test program in hospitals and
health departments. Infection Control and Hospital Epidemiology.
2003 Nov;24:814-818.
Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the
risk of tuberculosis among intravenous drug users with human immunodeficiency
virus infection. N Engl J Med.1989;320:545-50.
US Department of Health and Human Services. TB Respiratory
Protection Program in Health Care Facilities: Administrator’s Guide.
Cincinnati: US Department
of Health and Human Services, Public Health Service, Centers for
Disease Control and Prevention, National Institute for Occupational
Safety and Health, 1999. DHHS publication no. (NIOSH) 99-143.
Last Reviewed: 05/18/2008
Content Source: Division of Tuberculosis Elimination
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
|
